EyePoint Pharmaceuticals Inc. (EYPT) has stepped into the spotlight after reaching a new 52-week high on Thursday, December 4, 2025. The company's late-stage clinical programs and strengthened financial position have placed it firmly in focus as one to watch in the ophthalmology space.
Strong Move on the Screen
The stock, EYPT, featured on our site on January 30, 2025, when it was trading around $7.85. EYPT closed Thursday's trade at $16.72, up more than 15%, with trading volume surging past two million shares compared to its average of 1.25 million. The day's range stretched from $14.40 to $16.95, marking the upper end of its 52-week range. After hours, the stock held its ground at $16.87, adding another modest gain. The company's market capitalization stood at $1.38 billion.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.